University of California San Diego researchers have unveiled promising results for ION224, an experimental drug designed to treat metabolic dysfunction-associated steatohepatitis (MASH), a progressive liver condition affecting an estimated 115 million people worldwide. In a Phase 2 clinical trial, 78 percent of patients treated with ION224 demonstrated significant improvements in liver health over just 12 weeks, without requiring weight loss as a primary intervention.
The drug works by inhibiting acetyl-CoA carboxylase (ACC), a liver enzyme central to fat accumulation and inflammatory processes that lead to cirrhosis. This mechanism represents a departure from conventional approaches that emphasize lifestyle modification alone. Dr. Rohit Loomba, director of the NASH Research Center at UC San Diego Health, emphasized that ION224 directly targets the metabolic pathways driving liver damage, offering a fundamentally new therapeutic avenue for patients with limited treatment options.
Read the full article on GMJ Newsroom.
Was this article helpful?
